KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $149.1 million.

  • CRISPR Therapeutics AG's Total Current Liabilities rose 6987.54% to $149.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $149.1 million, marking a year-over-year increase of 6987.54%. This contributed to the annual value of $149.1 million for FY2025, which is 6987.54% up from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Total Current Liabilities stood at $149.1 million for Q4 2025, which was up 6987.54% from $119.0 million recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Total Current Liabilities ranged from a high of $150.9 million in Q3 2022 and a low of $83.1 million during Q1 2021
  • Its 5-year average for Total Current Liabilities is $116.0 million, with a median of $119.0 million in 2024.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Total Current Liabilities crashed by 2627.16% in 2023, and later surged by 6987.54% in 2025.
  • CRISPR Therapeutics AG's Total Current Liabilities (Quarter) stood at $119.9 million in 2021, then increased by 1.02% to $121.1 million in 2022, then fell by 10.17% to $108.8 million in 2023, then decreased by 19.31% to $87.8 million in 2024, then soared by 69.88% to $149.1 million in 2025.
  • Its Total Current Liabilities stands at $149.1 million for Q4 2025, versus $119.0 million for Q3 2025 and $104.4 million for Q2 2025.